This work was supported in part by a grant from the National Cancer Institute(R01CA200232-05);a DoD breast cancer grant(11895064)to C.G.M.and by grants from National Heart,Lung,and Blood Institute(HL-057832,HL-132871,and HL-13A781)to LAB.
Tamoxifen(TAM)is the first-line endocrine therapy for estrogen receptor-positive(ER+)breast cancer(BC).However,acquired resistance occurs in∼50%cases.Meanwhile,although the PI3K/AKT/mTOR pathway is a viable target fo...